In the HER2 overexpressing (IHC 3+) NCI-H2170 squamous cell lung carcinoma xenografts [14,15], mAb104-DX8951 resulted in significant tumour growth inhibition compared to the ADC control (IgG1-DX8951) (p = 0.0025) and numerically superior to trastuzumab (p = 0.533). Here, ERBB2 is linked to squamous cell lung carcinoma.